Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Net Margin: 2010-2025

Historic Net Margin for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to 3.04%.

  • Anika Therapeutics' Net Margin rose 9801.00% to 3.04% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.64%, marking a year-over-year decrease of 276.00%. This contributed to the annual value of -39.66% for FY2024, which is 2593.00% up from last year.
  • Per Anika Therapeutics' latest filing, its Net Margin stood at 3.04% for Q3 2025, which was up 26.77% from 2.40% recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Net Margin ranged from a high of 17.12% in Q2 2021 and a low of -558.26% during Q4 2023.
  • Its 3-year average for Net Margin is -69.51%, with a median of -8.81% in 2024.
  • Per our database at Business Quant, Anika Therapeutics' Net Margin plummeted by 35,229bps in 2022 and then skyrocketed by 49,494bps in 2024.
  • Over the past 5 years, Anika Therapeutics' Net Margin (Quarterly) stood at -9.03% in 2021, then tumbled by 35,229bps to -361.32% in 2022, then tumbled by 19,694bps to -558.26% in 2023, then surged by 49,494bps to -63.33% in 2024, then surged by 9,801bps to 3.04% in 2025.
  • Its Net Margin stands at 3.04% for Q3 2025, versus 2.40% for Q2 2025 and -3.50% for Q1 2025.